Alterity Therapeutics (ATHE) Long-Term Deferred Tax (2017 - 2018)

Alterity Therapeutics (ATHE) has 2 years of Long-Term Deferred Tax data on record, last reported at $26.0 million in Q2 2018.

  • For Q2 2018, Long-Term Deferred Tax rose 3.02% year-over-year to $26.0 million; the TTM value through Jun 2018 reached $26.0 million, up 3.02%, while the annual FY2018 figure was $26.0 million, 2.63% up from the prior year.
  • Long-Term Deferred Tax reached $26.0 million in Q2 2018 per ATHE's latest filing, up from $25.3 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $26.0 million in Q2 2018 and bottomed at $25.3 million in Q2 2017.